Neovasc (NVCN) – Newsfile
-
Neovasc Shareholders Approve Acquisition by Shockwave Medical
-
Shockwave Medical to Acquire Neovasc
-
Neovasc Announces Progress on COSIRA-II Clinical Trial
-
Neovasc Comments on European Heart Journal Publication
-
Neovasc Announces Third Quarter Financial Results and Provides Corporate Update
-
Neovasc Reducer Obtains U.S. Outpatient Reimbursement
-
Neovasc to Report Third Quarter Financial Results on November 10, 2022
-
Neovasc Provides Corporate Update Following Clinical Data Release
-
Neovasc to Participate in LSI Europe 2022 Emerging MedTech Summit
-
Neovasc Comments on New ICD-10-CM Diagnosis Codes for Refractory Angina
-
Neovasc Announces Key Events at TCT 2022
-
Neovasc Announces Second Quarter Financial Results and Provides Corporate Update
-
Neovasc to Report Second Quarter Financial Results on August 11, 2022
-
Neovasc Announces FDA Approval of Planned COSIRA II Sub-studies and Single Arm Registry to Allow Inclusion of Additional Specified Patient Populations
-
Neovasc Announces Direct Sales Operations in United Kingdom
-
Neovasc to Participate in Sidoti & Co. Summer Small Cap Virtual Investor Conference
-
Neovasc to Participate in H.C. Wainwright Global Investment Conference
-
Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule
-
Neovasc Announces First Quarter Financial Results and Provides Corporate Update
-
Neovasc to Report First Quarter Financial Results on May 12, 2022
-
Neovasc Comments on European Heart Journal Publication
-
Neovasc Announces Effective Date of Share Consolidation
-
Neovasc to Participate in Bloom Burton & Co. Healthcare Investment Conference
-
Neovasc Inc. Reports Results of Annual General and Special Meeting of Shareholders
-
Neovasc Announces Consolidation and Extension of Convertible Debt
-
Neovasc to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
-
Neovasc Announces German Reimbursement Renewal and Commercial Progress
-
Independent Publication Reports Neovasc Reducer(TM) Demonstrates Cost Savings
-
Neovasc Announces Complete Dismissal of Securities Class Action Complaint with Prejudice
-
Neovasc Announces Publication Supporting the Neovasc Reducer(TM) Device
-
Neovasc Announces Case Series of First U.S. Reducer Implants Published in Peer-Reviewed Journal
-
Neovasc to Participate in H.C. Wainwright BIOCONNECT Virtual Conference
-
Neovasc Announces First Patient Enrollment in COSIRA-II Trial
-
Neovasc to Participate in Sidoti December Virtual Microcap Conference
-
Neovasc Reducer(TM) System Receives National Reimbursement in France
-
Neovasc Granted Additional 180 Calendar Day Grace Period for Nasdaq Bid Price Compliance
-
The National Institute for Health and Care Excellence of the United Kingdom Provides Positive Guidance for Neovasc Reducer System
-
Neovasc Announces Third Quarter 2021 Financial Results and Provides Corporate Update
-
Neovasc to Report Third Quarter 2021 Financial Results on November 9, 2021
-
Neovasc Reducer(TM) Featured in Polish Heart Journal
-
Neovasc REDUCER-I Study Published in EuroIntervention Journal
-
Neovasc to Participate in 2021 Benzinga Healthcare Small Cap Conference
-
Neovasc Announces FDA Approval of COSIRA-II Clinical Trial
-
Neovasc to Participate in H.C. Wainwright & Co. 23rd Annual Global Investment Conference
-
Neovasc Announces Submission of COSIRA-II Protocol Supplement to FDA
-
Neovasc Announces Second Quarter 2021 Financial Results
-
Neovasc to Report Second Quarter 2021 Financial Results on August 10, 2021
-
Neovasc Announces New Appointments in Regulatory and Clinical Leadership
-
Largest Real-World Registry Supporting Neovasc Reducer(TM) Safety and Efficacy Outcomes Published in International Journal of Cardiology
-
Neovasc Provides Corporate Update
Back to NVCN Stock Lookup
